SCHEMBL4258099

SCHEMBL4258099

COc1ccc(C=CS(=O)(=O)NC(=O)c2ccc(Cl)cc2C)cn1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 9/20 0.46
FLT4 P35916 9/20 0.46
KDR P35968 9/20 0.46
MEN1 O00255 1/20 0.43
USP2 O75604 1/20 0.43
PABPC1 P11940 1/20 0.43
KMT2A Q03164 1/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
TUBB4A P04350 1/20 0.40
TUBB P07437 1/20 0.40
TUBA3C P0DPH7 1/20 0.40
TUBA1B P68363 1/20 0.40
TUBA4A P68366 1/20 0.40
TUBB4B P68371 1/20 0.40
TUBB3 Q13509 1/20 0.40
TUBB2A Q13885 1/20 0.40
TUBB8 Q3ZCM7 1/20 0.40
TUBA3E Q6PEY2 1/20 0.40
TUBA1A Q71U36 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4258092 1.00 FLT1 (0.46) FLT1FLT4KDRMEN1USP2
SCHEMBL4264681 0.91 FLT1 (0.48) FLT1FLT4KDRMEN1USP2
SCHEMBL4264675 0.91 FLT1 (0.48) FLT1FLT4KDRMEN1USP2
SCHEMBL4258496 0.83 SMN1; SMN2 (0.43) FLT1FLT4KDRMEN1USP2
SCHEMBL4258490 0.83 SMN1; SMN2 (0.43) FLT1FLT4KDRMEN1USP2
SCHEMBL4258093 0.82 NNMT (0.45) MEN1USP2PABPC1KMT2AMAOA
SCHEMBL4256696 0.80 CYP11B2 (0.57) FLT1FLT4KDRKMT2ACYP11B2
SCHEMBL4256693 0.80 CYP11B2 (0.57) FLT1FLT4KDRKMT2ACYP11B2
SCHEMBL363188 0.79 MAOB (0.60) MEN1USP2PABPC1KMT2AMAOA
SCHEMBL5415611 0.79 FLT1 (0.52) FLT1FLT4KDRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP claimed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US claimed
EP-1904471-B1 HETEROARYLETHENYL DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS HOFFMANN LA ROCHE (CH) 2009-10-21 EP disclosed
US-7208506-B2 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010564-A1 Heteroarylethenyl derivatives, their manufacture and use as pharmaceutical agents CYP3A43, CYP1A1, CYP3A5 FLT1 2692/4885FLT4 2521/4885KDR 1957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.